NASDAQ: NXGL · Industrial Applications and Services · 7 alerts · CIK 1468929
Share price
$3.93Close, Nov 16
Market cap
$2.11M
Shares outstanding
536.11KLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Nexgel, Inc. filings on SEC EDGAR ↗
NEXGEL, INC. reported a net loss of $5.68 million for the nine months ended September 30, 2026, compared to $2.03 million in the prior year, driven by significant increases in selling, general, and administrative expenses. Total assets grew to $23.90 million following a major $12.34 million increase in intangible assets, while the company underwent a 1-for-20 reverse stock split in October 2026.
Nexgel Interim CEO Brian Joseph Kieser Buys $733K of Stock
Brian Joseph Kieser, Interim CEO, bought 133,216 shares of Nexgel, Inc. at $5.50 a share, worth $733K in total on Nov 10, 2026. Shares held after the trade: 133,216.
Nexgel Insider steven mark glassman Buys $25K of Stock
steven mark glassman bought 4,546 shares of Nexgel, Inc. at $5.50 a share, worth $25K in total on Nov 10, 2026. Shares held after the trade: 12,379 (+58.0%).
NEXGEL announced a strategic recapitalization and update on a potential merger with Fountainhead LifeSciences, including its affiliates Sequence LifeScience and NVISION Biomedical Technologies. As part of the plan, holders of $14.125 million in convertible notes (95% of outstanding principal) agreed to convert their debt into common stock at $5.50 per share, contingent upon the completion of the merger.